Browsing Tag
Novartis
90 posts
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Avidity Biosciences (Nasdaq: RNA) opens access to del-zota in DMD44 as BLA filing nears
Avidity Biosciences launches U.S. access program for del-zota in DMD exon 44 patients. See how this ties into FDA submission plans and the Novartis acquisition.
Can psoriatic disease remission be redefined? Inside the shift toward zero activity in targeted domains
Discover how zero disease activity in one or more domains is reshaping psoriatic care, pharma strategy, and future treatment benchmarks.
Inhibrx Biosciences’ Ozekibart sets new benchmark in rare bone cancer treatment and advances toward 2026 BLA filing
Find out how Inhibrx Biosciences’ Ozekibart delivered breakthrough results in chondrosarcoma and is advancing toward a 2026 BLA filing—read more now!
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.
Can longevity biotech finally go mainstream — or is BioAge’s $250m shelf another warning sign of investor fatigue?
BioAge Labs (NASDAQ: BIOA) files a $250M shelf to fund aging-drug programs. Can disciplined financing revive investor faith in longevity biotech?
From IPO to $250M shelf: Can BioAge Labs keep investor faith in the race for anti-aging drugs?
BioAge Labs (NASDAQ: BIOA) files $250M mixed securities shelf to fuel its aging drug pipeline. See what it means for investors today.
Inside the Crucial Catch partnership: how the American Cancer Society and NFL are tackling cancer disparities with new grants
Discover how the American Cancer Society and NFL’s Crucial Catch program is boosting cancer screening access and saving lives nationwide.
The Max Foundation and Novartis deepen global cancer care partnerships with a pledge to reach 100,000 patients annually by 2030
The Max Foundation and Novartis pledge to expand global cancer care, targeting 100,000 patients annually by 2030 with systemic, equity-driven partnerships.
Kashiv BioSciences bets on Latin America with Cristália deal for Xolair biosimilar
Kashiv BioSciences partners with Brazil’s Cristália to commercialize omalizumab biosimilar ADL-018 in Latin America, targeting a $140M market opportunity.